

Program

2nd SASRO/SSRMP Joint Annual Meeting



20th Annual Meeting SASRO

50th Annual Meeting SSRMP

SASRO and SGSMP would like to thank all Companies and Sponsors !

alphabetical order



Science For A Better Life



Burgerstein Vitamine



MEDTECHCONSULTING.CH COSSMANN



ELEKTA

ico | c e t



INNOMEDICUS



IntraOp®



Kaiku

Created by NETMEDI



MERCK



OPASCA

PHILIPS

PTW



raditec radiation & technology



Sie - Rep GmbH
Hospital and X-Ray Accessories



SVMTRA / ASTRM

Schweizerische Vereinigung der Fachleute für med. tech. Radiologie
Association suisse des techniciens en radiologie médicale
Associazione svizzera per la tecnici di radiologia medica



PLAN 3rd FLOOR



BOOTHS

01	VARIAN	13	SIERP
02	KAIKU	14	MEDITRON
03	INNOMEDICUS	15	SOLUMEDICS
04	RADITEC	16	ZEISS
05	OPASCA	17	JANSSEN CILAG
06	ELEKTA	18	INTRAOP
07	RAYSEARCH	19	CONMEDICA
08	PHILIPS	20	BRAINLAB
09	MERCK	21	RT-SAFE
10	BURGERSTEIN	22	ACCURAY
11	MEDTECH	23	SVMITRA
12	PTW	24	ICOTEC
		25	MOELNYCKE
		26	QUALIFORMED



Conference Rooms OST + WEST



SPEAKERS ROOM



POSTERS/NURSE SEMINARS 2nd Floor!



COFFEE / DRINKS



'HIT THE TARGET' - Event



GOLD SPONSOR

VARIAN



SILVER SPONSOR

BAYER



BRONZE SPONSOR

ELEKTA

Scientific Committees

For Medical Physics

For SGSMP: Raphael Moeckli, Lausanne; Stefano Presilla, Bellinzona; Götz Kohler, Basel; Peter Manser, Berne

For SASRO: Giovanna Dipasquale, Geneva; Manfred Sassowsky, Inselspital, Berne

For Medical Radiation Oncology

Damien Weber, Villigen; Daniel Zwahlen, Chur; Gianfranco Pesce, Bellinzona; Paul Martin Putora, St. Gallen; Guenther Gruber, Zürich

For Radiation Biology

Yitzhak Zimmer, Inselspital, Berne

For RTTs

Sabine Krummenacher, Triemli; Arthur Sterchele, St. Gallen

For Nurses

Marianne Scharfenberger, Winterthur

Award Committees

SVMTRA Award

Ulrike Dechantsreiter, Lucerne; Arthur Sterchele, St. Gallen

Best Poster and Best Presentation Awards

For SGSMP: Goetz Kohler, Basel; Stefano Presilla, Bellinzona; Manfred Sassowsky, Berne


For SASRO: Oscar Matzinger, Vevey; Karl Beer, Biel

Abstracts available online



Zuverlässig
Konsistent
Effizient

WISSENSBASIERTE PLANUNG



Steigern Sie die Qualität. Senken Sie die Häufigkeit von Wiederholungen.

Die wissensbasierte Planung von RapidPlan™ öffnet das Tor für die nächste Generation der individualisierten Bestrahlungsplanung. Ärzte können nun verschiedene Arten von Krebs behandeln, indem sie wissens-basierte Planung nutzen und anwenden.

Durch die Bereitstellung von vorkonfigurierten Modellen kann RapidPlan Kliniken helfen, Variabilität bei der Bestrahlungsplanung zu verringern. Dadurch kann erneut eine höhere Konsistenz, Effizienz und Qualität bei der Patientenversorgung erreicht werden.

Optimieren Sie Ihre Planung!

VARIAN
medical systems

Erfahren Sie mehr über die Vorteile von Eclipse unter
www.varian.com info.europe@varian.com



THURSDAY, 25th August, 2016

12:00 Registration; Industrial Exhibition

12:30 – 12:55 Pre-Meeting Symposium (by Dr Sennewald) (Conference Room _OST)

Welcome (G Sennewald, S Bodis)

Focussed high frequency antenna arrays: A hint at the future (P Turner, G Sennewald)

The Search for Evidence for Radiotherapy and Hyperthermia *and*

Swiss Clinical Trials for HT and RT (N Datta)

Swiss Hyperthermia Network and Swiss HT Tumorboard (S Bodis, E Puric)

13:00 – 13:15 Opening Session (Conference Room _OST)

R Boucenna, Lausanne; Congress President SSRMP

G Gruber, Zurich; Congress President SASRO

13:15 – 14:30 SESSION 1 (Conference Room _OST): Combined 1

Chairs: U Schneider, Zurich; A Papachristofilou, Basel

13:15 – 13:30 1.1 Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: A systematic review with conventional and network meta-analyses

NR Datta¹, S Rogers¹, D Klingbiel², S Gómez¹, E Puric¹, S Bodis^{1,3}, ¹Centre for Radiation Oncology, KSA-KSB, Kantonsspital Aarau, Aarau, ²Swiss Group for Clinical Cancer Research (SAKK), Coordinating Centre, Bern, ³Department of Radiation Oncology, University Hospital, Zurich

13:30 – 13:45 1.2 Can tracking be beneficial in SBRT pancreas treatments?

Karava K, Ehrbar S, Riesterer O, Roesch J, Glatz S, Klöck S, Guckenberger M, Tanadini-Lang S; *University Hospital Zurich (USZ), Department of Radiation Oncology, Zurich*

13:45 – 14:00 1.3 Dosimetry of FLAH irradiation for studies on the biological effect induced in normal brain and GBM

K Petersson¹, P Montay-Gruel^{2,3}, M Jaccard^{1*}, MC Vozenin^{2,3}, T Buchillier¹, JF Germond¹, F Bochud¹, J Bourhis², C Bailat¹; ¹Institute of Radiation Physics (IRA), ²Department of Radiation Oncology, ³Radio-oncology laboratory, Lausanne University Hospital, Lausanne, Switzerland

14:00 – 14:15 1.4 Calculation of the “effective dose” delivered by IGRT in H&N and breast treatments

M Conrad^{1,2}, G Bolard³, M Nowak¹, B De Bari¹, W Jeanneret¹, JF Germond¹, F Bochud¹, R Moeckli¹; ¹Institute of Radiation Physics, Lausanne University Hospital, Lausanne, ²Université de Genève, Genève, ³Clinique de Genolier, Genolier, Switzerland

14:15 – 14:30 1.5 Impact of the radiation dose on hepatic perfusion evaluated using liver scintigraphy mebrofenin

B De Bari¹, Th Breuneval¹, M Zeverino², S Godin¹, J Prior³, J Bourhis¹, R Moeckli², M Ozsahin¹. ¹Radiotherapy Department, ²Medical Physics, ³Service de Médecine Nucléaire, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

14:30 – 15:15 Industrial Exhibition; Poster Exhibition; Coffee Break

15:15 – 17:00 SESSION 2 (Conference Room _OST): Clinical 1

Chairs: F Herrera, Lausanne; K Zaugg, Berne

- 15:15 – 15:30 2.1 Impact of the radiation dose on the pulmonary perfusion assessed using lung scintigraphy
B De Bari¹, S Godin¹, M Zeverino², Th Breuneval¹, J Prior³, Bourhis¹, R Moeckli², M Ozsahin¹. ¹Radiotherapy Department, ²Medical Physics, ³Service de Médecine Nucléaire, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- 15:30 – 15:45 2.2 Non-resected and R1 resected pancreatic adenocarcinoma: Feasibility and patients' outcome after radio-chemotherapy with high dose external radiotherapy (RT)
D Lauffer¹, S Thalman¹, P Kuhn¹, M Kueng², T Breuneval¹, PA Tercier¹, G Risse¹, B Egger³, AS Allal¹; ¹Service de radio-oncologie, ²Service d'oncologie, ³Service de chirurgie, HFR- hôpital fribourgeois; Switzerland
- 15:45 – 16:00 2.3 Long-term outcome of early stage glottic cancer treated with radiotherapy and/or surgery
M Shelan¹, E Mathier¹, L Anschütz², S Adrian², B Bojaxhiu¹, A Dal Pra¹, F Behrensmeier^{1,3}, M Caversaccio² DM Aebersold¹, R Giger², O Elicin¹; ¹ Department of Radiation Oncology and ² Department of Otorhinolaryngology-Head and Neck Surgery, Inselspital, Bern University Hospital, Switzerland, ³ Radiation-Oncology-Centre, Biel - Seeland - Berner Jura, Biel, Switzerland
- 16:00 – 16:15 2.4 Impact of the site of metastasis on prostate cancer-specific survival in patients treated with curative radiotherapy
M Pascale¹, C Azinwi², G Pesce², E Roggero¹, F Stoffel³, A Richetti²; ¹Oncology Unit and ²Radio-oncology Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona/Lugano, ³Urology Unit, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
- 16:15 – 16:30 2.5 Risk Factors for PEG-Dependency and Unplanned Hospitalizations in Patients with Head and Neck Cancer Who Underwent Gastrostomy Tube Installment
BK Shrestha¹, B Bojaxhiu¹, O Elicin¹, A Dal Pra¹, A Macpherson², B Heimgartner², R Giger³, DM Aebersold¹, K Zaugg¹; ¹Department of Radiation Oncology ²Department of Visceral Surgery and Medicine, Division of Gastroenterology and ³Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, Bern, Switzerland
- 16:30 – 16:45 2.6 Dose-escalated salvage radiotherapy for histologically proven macroscopic recurrence after radical prostatectomy: Clinical outcomes and toxicity results
M Shelan, S Odermat, B Bojaxhiu, O Elicin, DM Aebersold, A Dal Pra; Department of Radiation Oncology, Inselspital, Bern University Hospital, Switzerland
- 16:45 – 17:00 2.7 Safety and early efficacy of stereotactic radiosurgery in trigeminal neuralgia
Lavajo Vieira B¹, Ares C¹, Dipasquale G¹, Nouet P¹, Bijlenga P², Miralbell R¹; ¹Department of Radiation Oncology, ²Department of Neurosurgery, University Hospital of Geneva, Geneva, Switzerland

15:15 – 17:00 SESSION 3 (Conference Room _WEST): Physics 1

Chairs: L Wilke, Zurich; Y Kaeser, Zurich

- 15:15 – 15:30 3.1 Liquid filled ionization chamber 2D-array for patient specific QA for stereotactic treatment at CyberKnife®
V Magaddino, V Vallet, D Patin **Fehler! Textmarke nicht definiert.**, M Schopfer **Fehler! Textmarke nicht definiert.**, R Moeckli; Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland
- 15:30 – 15:45 3.2 Evaluating the actual direction distribution of the primary radiation for a Cyberknife-M6 using system log files
D Henzen¹, CC Zanella^{1,2}, D Schmidhalter¹, W Volken¹, PH Mackeprang¹, M Malthaner¹, MK Fix¹, P Manser¹; ¹Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, ²Institute for Biomedical Engineering, ETH and University of Zürich, Zürich, Switzerland

- 15:45 – 16:00 3.3 Monte Carlo model of a gantry for proton pencil beam scanning
C Winterhalter¹, S Safai¹, C Grassberger², D Oxley¹, DC Weber¹, T Lomax¹; ¹*Center for Proton Therapy, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland,* ²*Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA*
- 16:00 – 16:15 3.4 Dose and energy measurements in radiotherapy by a combination of TLD100 and TLD100H
P Hauri, U Schneider; *Faculty of Science, Universtiy of Zurich, Zurich, Switzerland, Radiotherapy Hirslanden, Hirslanden Medical Center, Aarau, Switzerland*
- 16:15 – 16:30 3.5 Comparison of two automated treatment planning solutions for complex head and neck cancer
M Zamburlini¹, J Krayenbuehl¹, S Graydon¹, I Norton², G Studer¹, S Kloeck¹, M Guckenberger¹; ¹*University Hospital Zurich, Department of Radiation and Oncology, Zurich, Switzerland,* ²*Philips Radiation Oncology Systems, Fitchburg, Wisconsin, USA*
- 16:30 – 16:45 3.6 Concepts and principles of deformable image registration QA
JF Germond, R Moeckli; *Institute of Radiation Physics Lausanne University Hospital, Lausanne, Switzerland*
- 16:45 – 17:00 3.7 Comparison of two deformable registration software using an in-house “deformable phantom”
N Koutsouvelis, M Rouzaud; *Radiation therapy department, Geneva University Hospital, Geneva, Switzerland*
- 17:00 – 18:30 SRO General Assembly (Conference Room _OST)**
- 17:00 – 18:30 SSRMP General Assembly (Conference Room _WEST)**

XOFIGO® ist indiziert für die Behandlung von Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) und symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen.^{1*}



Verschreiben Sie Xofigo® bei den ersten Anzeichen einer Progression unter einer neuartigen Antihormontherapie

LEBEN.

VERLÄNGERT.²

VERLÄNGERN SIE DAS MEDIANE GESAMTÜBERLEBEN UM 3,6 MONATE²

• Xofigo® verlängert das mediane Gesamtüberleben im Vergleich zum besten Therapiestandard allein auf 14,9 Monate.²

* Bei nicht orchiektomierten Patienten soll eine antiandrogene Behandlung zur Suppression des Testosteronspiegels auf Kastrationsniveau weitergeführt werden.

1. Fachinformation Xofigo® (Radium-223-Dichlorid), www.swissmedinfo.ch. 2. Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine 2013;369:213

Gekürzte Fachinformation XOFIGO®

Wirkstoff: Radium Ra-223-Dichlorid. **Indikation:** Xofigo ist indiziert für die Behandlung von Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) und symptomatischen Knochenmetastasen ohne bekannte viszerale Metastasen. Bei nicht orchiektomierten Patienten soll eine antiandrogene Behandlung zur Suppression des Testosteronspiegels auf Kastrationsniveau weitergeführt werden. **Dosierung/Anwendung:** 6 Injektionen mit jeweils 55 kBq pro kg Körpergewicht in Abständen von 4 Wochen. Für die Anwendung bei Kindern, Jugendlichen und bei Frauen besteht keine Indikation. Xofigo ist ein Radiotherapeutikum. Anwendung nur durch autorisiertes Personal mit entsprechender Bewilligung des Bundesamtes für Gesundheit. **Kontraindikationen:** Schwangerschaft, Frauen, die schwanger sein könnten, Stillzeit. **Warnhinweise/Vorsichtsmassnahmen:** Knochenmarksuppression, vor Beginn der Behandlung und vor jeder weiteren Dosis muss eine hämatologische Untersuchung durchgeführt werden. Nicht untersucht bei Patienten mit Morbus Crohn oder Colitis ulcerosa. Bei Rückenmarkskompression vor Beginn oder Wiederaufnahme der Behandlung mit Xofigo eine der klinischen Indikation entsprechende Standardbehandlung durchführen. Knochenfrakturen vor Beginn oder Wiederaufnahme der Behandlung mit Xofigo orthopädisch stabilisieren. Unerwünschte Wirkungen auf Hoden und Spermien möglich, zuverlässige Kontrazeption notwendig. **Unerwünschte Wirkungen:** Sehr häufig: Thrombozytopenie, Diarrhoe, Erbrechen, Übelkeit. Häufig: Neutropenie, Panzytopenie, Leukopenie, Reaktionen an der Injektionsstelle. Gelegentlich: Lymphopenie **Interaktionen:** Sicherheit und Wirksamkeit einer Kombinationsbehandlung mit Xofigo plus Chemotherapie sind nicht untersucht, Wirkungen bezüglich Knochenmarksuppression können sich addieren. **Packungen:** 1 Injektionsflasche à 6 ml Lösung mit 6600 kBq. Verkaufskategorie A **Zulassungsinhaber:** Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zürich. Ausführliche Information auf www.swissmedinfo.ch. L.CH.MKT.ONC.01.2016.0358-DE/EN/FR/IT



L.CH.MKT.ONC.06.2016.0412-DE/FR/IT

 **Xofigo®**
Radium-223-dichlorid

FRIDAY, 26th August, 2016

07:30 Registration

08:00 – 09:00 Industrial Exhibition (Exhibition Pass – ‘Win an iPad’); Poster Exhibition

08:00 – 08:30 Refresher Course 1 (Conference Room _OST)

a 25’ Radiotherapy in prostate cancer: More dose, less fractions?

A Dal Pra, *Inselspital and University Hospital, Bern, Switzerland*

08:00 – 08:30 Refresher Course 2 (Conference Room _WEST)

a 25’ Hit the right target: PET-CT and MRI in treatment planning

HJ Veas, *Klinik Hirslanden, Zürich, Switzerland*

08:30 – 08:55 RTsafe Symposium (Conference Room _OST)

a 25’ Confidence building and peace-of-mind that you effectively ‘Hit the Target’ in cranial and spine SRS – Pseudo-in-vivo individualized dosimetry by RTsafe

E Pappas, *Founding Chairman and Chief Scientific Officer RTsafe, Greece*

09:00 – 10:15 SESSION 4 (Conference Room _OST): Clinical 2

Chairs: MC Valli, Bellinzona; L Plasswilm, St. Gallen

09:00 – 09:15 4.1 Timing of radiotherapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: long term results from IBCSG Trials VI and VII

P Karlsson¹; BF Cole²; KN Price³; RD Gelber⁴; AS Coates⁵; A Goldhirsch⁶; M Castiglione⁷; M Colleoni⁸; G Gruber⁹;
¹Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Mathematics and Statistics, University of Vermont, Burlington, USA, ³IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Boston, USA, ⁴IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard TF Chan School of Public Health, Boston, USA, ⁵IBCSG and University of Sydney, Sydney, Australia, ⁶Program for Breast Health (Senology), European Institute of Oncology and IBCSG, Milan, Italy, ⁷IBCSG, Bern, Switzerland, ⁸Division of Medical Senology, European Institute of Oncology and IBCSG, Milan, Italy, ⁹Institute of Radiotherapy, Klinik Hirslanden, Zürich, Switzerland

09:15 – 09:30 4.2 Hit the “lung” target: IOSI experience

F Martucci¹, S Cima¹, P Fanti¹, MC Valli¹, G Pesce¹, C Azinwi¹, K Yordanov¹, B Muoio¹, S Presilla², A Richetti¹;
¹Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona-Lugano, ²EOC, Medical Physics Unit, Bellinzona, Ticino; Switzerland

09:30 – 09:45 4.3 Prognostic factors in breast cancer associated with brain metastases

O Santa Cruz¹, P Tsoutsou¹, S Anchisi², K Khanfir³, L Negretti⁴, C Girardet⁵, O Ozsoy³, M Ozsahin⁶; ¹Radiation Oncology, Hopital Neuchatelois, La Chaux-De-Fonds, ²Medical Oncology, Centre Hospitalier du Valais Romand (CHVR), Sion, ³Radiation Oncology, Centre Hospitalier du Valais Romand (CHVR), Sion, CH, ⁴Radiation Oncology, Clinica Luganese Moncucco, Lugano, ⁵Pathology, Centre Hospitalier du Valais Romand (CHVR), Sion, ⁶Radiation Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland

09:45 – 10:00 4.4 Oligorecurrent nodal prostate cancer: long term results of an elective nodal irradiation approach

S Tran, T Falco, G Lamanna, L Lestrade, R Miralbell, T Zilli; *Radiation Oncology, Geneva University Hospital, Geneva, Switzerland*

10:00 – 10:15 4.5 Miss the target in old age breast cancer patients: the experience of the Ticino Breast Unit
S Cima^{1,3}, B Muoio¹, P Fanti^{1,3}, A Richetti^{1,3}, A Vanetti^{2,3}, C Canonica^{2,3}, C Azinwi¹, F Martucci¹, K Yordanov¹, G Pesce¹, MC Valli^{1,3}; ¹*Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona-Lugano*, ²*Gynaecology Department, Ospedale Regionale Bellinzona e Valli, Bellinzona*, ³*Centro di Senologia della Svizzera Italiana (CSSI), Switzerland*

10:15 – 10:45 Industrial Exhibition; Poster Exhibition; Coffee Break

10:45 – 12:00 SESSION 5 (Conference Room _OST): Combined 2

Chairs: Th Zilli, Geneva, M Aspradakis, Lucerne

10:45 – 11:00 5.1 Comparison of MLC and couch tracking for SBRT prostate cancer
S Schmid^{1,2}, S Ehrbar^{1,3}, S Klöck^{1,3}, M Guckenberger^{1,3}, S Tanadini-Lang^{1,3}; ¹*University Hospital Zurich, Department of Radiation Oncology, Zürich*, ²*ETH Zürich, Department of Physics, Zurich*, ³*University of Zurich, Faculty of Science, Zurich, Switzerland*

11:00 – 11:15 5.2 Prospective study on the clinical impact of ¹⁸F-fluorocholine (FCH) PET/CT on treatment management in biochemical recurrent prostate cancer: hit the right target for the right patient
B Muoio, C Azinwi, G Pesce, F Martucci, S Cima, MC Valli, P Fanti, K Yordanov, A Richetti; *Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona-Lugano; Switzerland*

11:15 – 11:30 5.3 The breath hold method to reduce the heart dose for left sided breast radiotherapy
C Tamburella, J Abel, G Guibert, L Pion, O Santa Cruz, J Trouillot, M Voelin, P Weber, P Tsoutsou; *Hopital Neuchatelois, La chaux de Fonds, Switzerland*

11:30 – 11:45 5.4 Intraindividual comparison of ¹¹C-Acetate and ¹⁸F-Fluorocholine PET/CT and PET/MRI studies for early recurrent prostate cancer after primary treatment
G Lamanna^{1,2}, V Garibotto^{3,4}, C Tabouret-Viau³, O Rager³, S Jorcano⁵, HJ Veas¹, Y Seimbille³, H Zaidi^{3,4}, O Ratib^{3,4}, F Buchegger^{3,4}, R Miralbell^{1,4,5}, T Zilli^{1,4}; ¹*Radiation-Oncology, University Hospital of Geneva, Geneva, Switzerland*, ²*Radiation-Oncology, IRCCS San Martino - IST National Cancer Research Institute, Genoa, Italy*, ³*Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland*, ⁴*Faculty of Medicine, Geneva University, Geneva, Switzerland*, ⁵*Radiation Oncology, Teknon Oncologic Institute, Barcelona, Spain*

11:45 – 12:00 5.5 Potential of computed tomography with iterative metal artifact reduction algorithm for proton therapy of patients with metal implants
S Belloni^{1,2}, M Peroni², A Bolsi², T Niemann³, D Engelhardt³, N Fachouri², R Perrin², M Walser², G Fattori², RA Kubik-Huch³, AJ Lomax², and DC Weber^{2,4,5}; ¹*Department of Physics and Astronomy, University of Bologna, Italy*, ²*Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland*, ³*Department of Radiology, Cantonal Hospital Baden, Baden, Switzerland*, ⁴*Radiation Oncology Inselspital, Bern, Switzerland*, ⁵*Radiation Oncology, University Hospital of Zurich, Switzerland*

08:30 – 10:00 General Assembly IG Pflege RAO (Conference Room _WEST)

10:30 – 12:00 SESSION 6 (Conference Room _WEST): Nursing

Chairs: D. Miletic, Zürich; A. Stier, Zurich

a 30' 6.1 Krebs? Das Krebstelefon ist da mit Wissen und Fürsorge
A Zahno, Leiterin Krebstelefon, *Krebsliga Schweiz, Switzerland*

a 45' 6.2 Evidenzbasierte Pflege – Entzauberung der Wissenschaft
A Gutierrez, *Klinik Hirslanden, Aarau, Switzerland*

12:00 – 14:00 Workshop MOELNLYCKE; Registration directly at Booth 25

12:00 – 12:45 Industrial Exhibition; Lunch; Poster Exhibition

12:45 – 14:15 LUNCH SYMPOSIA Conference Room _OST

12:45 – 13:40 VARIAN – GOLD SPONSOR

Transforming Knowledge into Action

RapidPlan™ Knowledge Based Planning: an Innovative Tool for Modern Radiotherapy

A Fogliata, *Humanitas Research Hospital and Cancer Center, Milan, Italy*

Preliminary experience of Adaptive Radiotherapy simulations with the new Velocity platform

E Cagni, *IRCCS-ASMIN, Institute in advanced technologies and models of care in oncology, Reggio Emilia, Italy*

13:45 – 14:15 BAYER – SILVER SPONSOR

Radium-223 in castration-resistant prostate cancer: A radiation oncologist's perspective

M Sumila, *Klinik Hirslanden, Zurich, Switzerland*

12:45 – 14:15 LUNCH SYMPOSIA Conference Room _WEST

12:45 – 13:10 MERCK

10 Years Immunotherapy in Head & Neck Cancer – Concurrent systemic treatment and radiotherapy in locally advanced SCC

J Bourhis, *CHUV, Lausanne, Switzerland*

13:15 – 13:40 BRAINLAB

Brain Mets Planning and ETX

Stereotactic Radiosurgery Developments in the Treatment of Brain Metastases

Th Gevaert, *UZ Brussel, Brussels, Belgium*

13:45 – 14:10 ACCURAY

Accuray Last Breaking News

S Reid, *Product Marketing Manager, Accuray*

14:30 – 15:30 SESSION 7 (Conference Room _OST): Combined 3

Chairs: S Bulling, Eaux-Vives, N Andratschke, Zurich

14:30 – 14:45 7.1 Prone breast automatic segmentation of organs at risk including heart and coronary vessels: similarity indexes, contouring times and dose volume parameters

X Wang^{*1}, G Dipasquale*, V Chatelain-Fontanella*, O Fargier-bochaton*, R Miralbell*

* *Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland, ¹Department of Radiation Oncology, Tianjin Union Medical Center, Tianjin, China*

14:45 – 15:00 7.2 Estimation of late effects for MERT and photon plans in radiotherapy of the breast and chest wall
A Joosten, S Müller, D Henzen, W Volken, D Frei, K Lössl, P Manser, MK Fix; *Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Switzerland*

15:00 – 15:15 7.3 PET/CT-guided SIB-IMRT Combined with Concurrent 5-FU/MMC for the Treatment of Anal Cancer: a Single Institution Experience
J Beer, M Zimmermann, D Zwahlen, C Oehler; Department of Radiation Oncology, Kantonsspital Graubünden, Chur, Switzerland

15:15 – 15:30 7.4 Radiomics of CT perfusion maps
M Nesteruk¹, O Riesterer¹, R Bundschuh⁴, P Veit-Haibach^{2,3}, M Hüllner², G Studer¹, S Stieb¹, S Glatz¹, M Pruschy¹, M Guckenberger¹, S Tandini-Lang¹; ¹Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland, ²Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Switzerland, ³Department of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland, ⁴Department of Nuclear Medicine, University Hospital Bonn, Germany

14:30 – 15:30 **SESSION 8 (Conference Room _WEST): RTT**

Chairs: S. Berweger, Winterthur; Ch. Winter, Chur

14:30 – 14:42 8.1 Clinical implementation of an optical surface monitoring system (OSMS[®], VARIAN) in breast irradiation
A Tini, I Pytko, S Lang, C Winter, M Guckenberger, C Linsenmeier; Department of Radiation Oncology, University Hospital Zürich, Switzerland

14:42 – 14:54 8.2 Stability in positioning for lung radiosurgery (SBRT) patients
S Roosenthaler, S Khan, L Vugts, G Lutters, S Bodis, E Rabe; Radio-Onkologie Zentrum KSA-KSB, Kantonsspital Aarau, Switzerland

14:54 – 15:06 8.3 Validation of patient preparation and setup verification in SBRT for liver tumors – Case report
Panizza D¹, Colleoni P¹, Yordanov K², Valli MC², Pupillo F¹, Gaudino D¹, Moretto S², Rottoli G², Presilla S¹, Richetti A²; ¹Ente Ospedaliero Cantonale, Medical Physics Unit, Bellinzona, Switzerland; ²Oncology Institute of Southern Switzerland, Radiation Oncology Unit, Bellinzona-Lugano, Switzerland

15:06 – 15:18 8.4 Multi radiotherapy modalities treatment for multi targets in malignant pheochromocytoma setting – case report
Soares Rodrigues J¹, Durham A¹, Leal S¹, Zulliger C¹, Patin D², Ozsahin M¹, Bourhis J¹; ¹Department of Radiation Oncology, CHUV and University of Lausanne, Lausanne, Switzerland; ²Institute of Radiation Physics, CHUV and University of Lausanne, Lausanne, Switzerland

15:18 – 15:30 8.5 Hypofractionated stereotactic radiotherapy feedback for the treatment of liver tumors using backup gating and auto hold beam
A Guerreiro, E Wyniger, A Dubouloz, R Miralbell, T Zilli, L Lestrade; HUG Radio-Oncologie, Geneva, Switzerland

14:30 – 15:30 **Seminar 1 – Nursing (Seminar room – 2nd floor)**

6.3 Natürlich essen während der Strahlentherapie – Vortrag mit Kostproben
E. Fischer, Autorin von Kochbüchern und Essensratgebern, Wien, Österreich

15:30 – 16:00 **Industrial Exhibition; Poster Exhibition; Coffee Break**

15:30 – 16:30 **Workshop MOELNLYCKE; Registration directly at Booth 25**

16:30 – 17:00 **Seminar 2 – Nursing (Seminar room – 2nd floor)**

6.4 Mepitel Film vs standard treatments for the prevention and cure of skin toxicity in postoperative treatment of breast cancer: a phase III study
G. Presta, A Puliatti; D Valcarengi, S Cima, A Richetti, R Guggiari, MC Valli. IOSI, Bellinzona, Switzerland

16:00 – 17:15 **SESSION 9 (Conference Room _OST): Physics 2**

Chairs: A Bolsi, Villigen, F Verdun, Lausanne

- 16:00 – 16:15 9.1 Implementation of a complete time-effective dosimetric verification system for the commissioning and routine verification of Multiple Metastases Element (BrainLab)
S Alonso-Arrizabalaga, N Lomax, Z Girbau-Garcia, J McNamara, S Rogers, G Lutters, S Bodis; *RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland*
- 16:15 – 16:30 9.2 Bench-marking an automated planning tool for multiple brain metastases against an established multiple isocenter dynamic conformal arc technique
N Lomax, S Alonso, J McNamara, S Rogers, G Lutters, S Bodis; *Radio-Onkologie-Zentrum KSA-KSB, Kantonsspital Aarau, Switzerland*
- 16:30 – 16:45 9.3 High dose-per-pulse electron beam dosimetry – A saturation model for the Advanced Markus ionization chamber
K Petersson¹, M Jaccard¹, JF Germond¹, T Buchillier¹, F Bochud¹, J Bourhis^{2,3}, MC Vozenin^{2,3}, C Bailat¹; ¹*Institute of Radiation Physics (IRA), Lausanne University Hospital, Lausanne*, ²*Department of Radiation Oncology, Lausanne University Hospital, Lausanne*, ³*Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland*
- 16:45 – 17:00 9.4 Electron dosimetry with Gafchromic EBT3 films: energy and dose-rate dependence
M Jaccard¹, K Petersson¹, T Buchillier¹, JF Germond¹, T Duran Ramiro¹, MC Vozenin^{2,3}, J Bourhis^{2,3}, F Bochud¹, C Bailat¹; ¹*Institute of Radiation Physics (IRA), Lausanne University Hospital, Lausanne*, ²*Department of Radiation Oncology, Lausanne University Hospital, Lausanne*, ³*Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital Lausanne, Switzerland*
- 17:00 – 17:15 9.5 Comparison of photon MLC and cut-out collimated electron beams for standard electron treatments
S Müller¹, MK Fix¹, D Henzen¹, D Frei¹, D. Frauchiger¹, K Lössl¹, MFM Stampanoni², P Manser¹; ¹*Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern*, ²*Institute for Biomedical Engineering, ETH Zürich and PSI, Villigen, Switzerland*

16:00 – 17:15 **SESSION 10 (Conference Room _WEST): Radiobiology**

Chairs: M. Medová, Bern; M. Pruschy, Zurich

- 16:00 – 16:25 I.1 'HIT THE TARGET': The biologist's perspective
Invited speaker: S. Rottenberg, Berne; Switzerland
- 16:25 – 16:37 10.1 The role of the MET receptor tyrosine kinase in tumor resistance to radiation therapy: a phosphoproteomic approach
E Orlando^{1,2}, A Bensimon², M Medová¹, DM Aebersold¹, R Aebersold², Y Zimmer¹; ¹*Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland*, ²*Institute of Molecular Systems Biology, ETH Zürich, Switzerland*
- 16:37 – 16:49 10.2 Involvement of MET signaling in the HIF-1alpha pathway
A Glück^{1,2}, M Medová^{1,2}, A Quintin^{1,2}, E Orlando^{1,2}, D Leiser¹, DM Aebersold^{1,2}, Y Zimmer^{1,2}; ¹*Department of Radiation Oncology, Inselspital*, ²*Department of Clinical Research, Radiation Oncology, University of Bern, Bern, Switzerland*
- 16:49 – 17:01 10.3 Regulation of the Oncogene Carnitine Palmitoyltransferase 1C under hypoxia involves HIF1 alpha and p53
N Chang, D Dudka, DM Aebersold, J Feng, K Zaugg; *Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*
- 17:01 – 17:13 10.4 Dose-Rate Effect of Novel Radiation Technologies: Relevance for the Clinical Use
D Dudka, N Chang, J Feng, K Zaugg; *Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*

17:15 – 18:30 General Assembly SASRO (Conference Room _OST)

18:45 / 19:15 Bus transfer to Social Dinner at Water Castle Wyher (with ticket only)

19:30 – 20:00 Aperero

20:00 Dinner



VERSA HD

MEETS ITS PERFECT MATCH

Versa HD

The powerful combination of Versa HD™ and Monaco® delivers a unique blend of unrivaled dose delivery and intelligent dose planning. With the ultra-low transmission of Agility™ and Monaco's Monte Carlo accuracy, dose delivery to the target can be precisely controlled while ensuring surrounding anatomy is protected. Together, they make dynamic and stereotactic techniques not only possible but routine practice. GO BEYOND with Versa HD and Monaco.

VISITVERSAHD.COM

451337 114 30 Rev03.16



SATURDAY, 27th August, 2016

07:45 – **Registration**

08:15 – 10:15 **Symposium ‘HIT THE TARGET’ (Conference Room)**

Chairs: D. Weber, Villigen, SASRO President; P. Manser, Bern, SSRMP President

08:15 – 08:45 HIT THE TARGET: The medical physicist’s perspective

a 25’ I.2 Invited speaker: W. Verbakel, *Amsterdam, The Netherlands*

08:45 – 09:15 HIT THE TARGET: Staffing/Education/Quality

a 25’ I.3 Invited speaker: M. Coffey, *Dublin, Ireland*

09:15 – 09:45 HIT THE TARGET: High dose to the target

a 25’ I.4 Invited speaker: M. Guckenberger, *Zürich, Switzerland*

09:45 – 10:15 HIT THE TARGET: Radioimmunotherapy

a 25’ I.5 Invited speaker: F. Lohr, *Modena, Italy*

10:15 – 11:00 **Industrial Exhibition; Poster Exhibition; Coffee Break**

11:00 – 12:30 **SESSION 11 (Conference Room): Combined 4**

Chairs: D Zwahlen, Chur, S Kloeck, Zürich

11:00 – 11:15 11.1 Prevention of acute dermatitis with Noviphenone[®], a proprietary Camellia Sinensis extract, in female patients with breast cancer undergoing adjuvant radiotherapy
G Naef¹, UE Gasser², HE Holzgang³, DR Zwahlen¹, ¹ *Department of Radiation Oncology, Kantonsspital Graubünden, Chur;* ² *ClinResearch LTD, Aesch;* ³ *Novelpharm AG, Schlieren; Switzerland*

11:15 – 11:30 11.2 ITV, MidV, gating or tracking - what to use when?
S Ehrbar^{1,2}, A Tartas^{1,3}, S Stark^{1,2}, O Riesterer^{1,2}, S Klöck^{1,2}, M Guckenberger^{1,2}, S Tanadini-Lang^{1,2}; ¹ *Department of Radiation Oncology, University Hospital Zurich, Zürich,* ² *University of Zürich, Faculty of Science, Zürich, Switzerland,* ³ *University of Warsaw, Faculty of Physics, Warsaw, Poland*

11:30 – 11:45 11.3 Combination of Stereotactic Radiotherapy and Targeted Therapy: Patterns-of-care Survey among Swiss and German Clinics
SGC Kroeze¹, C Fritz¹, N Andratschke¹, U Nestle², T Brunner², M Guckenberger¹; ¹ *University Hospital Zürich, Department of Radiotherapy, Switzerland;* ² *University Hospital Freiburg, Department of Radiotherapy, Germany*

11:45 – 12:00 11.4 Clinical commissioning of MR-Only Prostate treatment planning workflow
G Bolard, S Bulling, N Hejira; *Clinique de Genolier, Switzerland*

12:00 – 12:15 11.5 Reducing treatment delivery times in prostate cancer robotic SBRT
PH Mackeprang¹, D Terribilini¹, E Herrmann², O Elicin², A Jensen², D Henzen¹, D Schmidhalter¹, M Malthaner¹, S Angelmann², S Fankhauser², MK Fix¹, P Manser¹, DM Aebersold², A Dal Pra²; ¹ *Division of Medical Radiation Physics and* ² *Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland*

12:15 – 12:30 11.6 Radiotherapy infrastructure and human resources in Switzerland – Present status and its projected computations for 2020

NR Datta¹, S Khan¹, D Marder¹, D Zwahlen², S Bodis^{1,3}; ¹RadioOnkologieZentrum, KSA-KSB, Kantonsspital Aarau, Aarau; ²Department of Radiotherapy, Kantonsspital Graubünden, Chur; ³Department of Radiation Oncology, University Hospital Zurich

12:30 – 12:50 **Awards, 'Win an iPad'; 'Hit the Target' (Conference Room)**

Moderator: G Gruber

12:50 – 13:00 **FAREWELL (Conference Room)**

P Manser (President SSRMP)

D Weber (President SASRO)

STRAHLENTHERAPIE RADIOTHERAPY 4.0

initiated by
 OPASCA

„By providing advanced holistic information systems for clinical workflows, we are changing the way of treatment in radiotherapy to make processes safer, more efficient and patient-centered.“

– Dr. Alexej Swerdlow
Founder and CEO of OPASCA

Visit OPASCA at SASRO Meeting 2016 | 3rd floor | booth 05

**Thanks for your participation
and see you next year!**